|Free Dividend Report|
|Stock Splits Calendar|
|PTX Stock Split History|
|Preferred Stock Newsletter|
|PTX Options Chain|
|Stock Message Boards|
PTX (PTX) has 2 splits in our PTX split history database. The first split for PTX took place on March 10, 2010. This was a 1 for 2 reverse split, meaning for each 2 shares of PTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 500 share position following the split. PTX's second split took place on October 14, 2016. This was a 1 for 10 reverse split, meaning for each 10 shares of PTX owned pre-split, the shareholder now owned 1 share. For example, a 500 share position pre-split, became a 50 share position following the split.
When a company such as PTX conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the PTX split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PTX shares, starting with a $10,000 purchase of PTX, presented on a split-history-adjusted basis factoring in the complete PTX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-60.32%|
|Pernix Therapeutics Holdings is a pharmaceutical company focused on the acquisition, development and commercialization of prescription drugs, primarily for the U.S. market. Co. targets therapeutic areas such as central nervous system, including pain, psychiatry and neurology. Co.'s branded products include: Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor (doxepin), non-narcotic, non-scheduled and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet (sumatriptan/naproxen sodium), a medication indicated for the acute treatment of migraine pain and inflammation. According to our PTX split history records, PTX has had 2 splits.|
|PTX Split History Table|
|03/10/2010||1 for 2|
|10/14/2016||1 for 10|
|Healthcare Stock Splits|
|PTX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: PTX shares outstanding history